Navigation Links
Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
Date:11/3/2011

THE WOODLANDS, Texas, Nov. 3, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Dr. David Powell, senior vice president of metabolism research, will present data from clinical and preclinical studies of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), at the Cambridge Healthtech Institute's Diabetes Drug Discovery conference in Boston, Massachusetts on Friday, November 4, 2011.

In clinical studies to date, LX4211 has demonstrated a favorable safety profile and beneficial effects on multiple parameters of glycemic control and cardiovascular health.  Recent studies in healthy subjects have shown that LX4211 substantially decreases postprandial glucose levels without hypoglycemia and substantially reduces triglycerides, results that have not been reported for SGLT2-selective inhibitors.  Data from a mechanistic study in patients with type 2 diabetes demonstrated that a single dose of LX4211 significantly increased circulating levels of GLP-1 (active and total) and PYY, important regulators of glycemic and appetite control.  In addition, postprandial release of GLP-1 and PYY from the gastrointestinal (GI) tract has been observed in preclinical studies of SGLT1 knockout mice but not in SGLT2 knockout mice, indicating that inhibition of SGLT1 function may trigger the postprandial release of these important regulators of glycemic and appetite control.

For more information on this program or to download a copy of the presentation, please visit www.lexpharma.com.

About Lexicon
Lexicon is a biopharmaceutical company focused on disco
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , 21 de noviembre de 2014 /PRNewswire/ ... ensayos clínicos externalizados y tecnologías eClinical, ha indicado ... de ,seguimiento inteligente, para el seguimiento basado en ... inteligente amplía el concepto del seguimiento basado en ... de las visitas de seguimiento o cambio de ...
(Date:11/22/2014)... Nov. 21, 2014 MEDITE Group acquired by CytoCore, ... and the 3 rd quarter sales ended September 30, ... $448,000 for the nine months ended September 2014 and a ... our 3 rd quarter is usually a seasonable weak ... July into September for many countries worldwide, we are proud ...
(Date:11/22/2014)... Nov. 21, 2014 Many power shifts ... growing influence of patients in the biopharmaceutical market ... Now, more than ever, understanding how to effectively ... products is essential. According to ... benchmarked companies spent about two-thirds of their patient-focused ...
Breaking Medicine Technology:El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2
... , NEW YORK, ... research report is available in its catalogue: , ... , http://www.reportlinker.com/p0164212/Chiral-Technology---International-Technology--Market-Trends.html , The fast developing ... of activity with pharmaceutical companies adding chiral expertise to ...
... , NEW YORK, ... research report is available in its catalogue: , ... of Market Trends & Opportunities , http://www.reportlinker.com/p0164272/Hepatitis-C-Virus-And-Therapeutics---A-Global-Update-of-Market-Trends--Opportunities.html ... years of meager clinical outcomes owing to lack of ...
Cached Medicine Technology:Reportlinker Adds Chiral Technology - International Technology & Market Trends 2Reportlinker Adds Chiral Technology - International Technology & Market Trends 3Reportlinker Adds Chiral Technology - International Technology & Market Trends 4Reportlinker Adds Chiral Technology - International Technology & Market Trends 5Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 8
(Date:11/22/2014)... November 22, 2014 Discount-Dress.com is ... of the firm is to increase the company’s online market ... a new selection of bridesmaid dresses and announced a bridesmaid ... is valid until Dec. 30, 2014. All the dresses from ... inexpensive. , In fact, Discount-Dress.com is very good at ...
(Date:11/22/2014)... New York, New York (PRWEB) November 22, 2014 ... use of power morcellators ( http://www.morcellatorlawsuit2015.com ) in ... than 450 new signatures since the end of October, ... people had signed the petition as of November 21st, ... October 31st, when 86,042 supporters had signed on to ...
(Date:11/22/2014)... 2014 Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) ... allegedly developed Type 2 diabetes due to its use ... now underway in U.S. District Court, District of South ... the litigation will convene its next Status Conference on ... Lead Counsel for Plaintiffs and Defendants to meet and ...
(Date:11/22/2014)... Forbes Living TV and featured ... that Ashley Lombardo and friend Candy Sherman are the ... Lombardo entered friend Candy Sherman to receive a generous ... her friend is courageously battling lung cancer and raising ... medical bills piling up and the constant struggle to ...
(Date:11/22/2014)... Developers and plugin specialist of Final Cut ... 3D Model bringing the impossible to FCPX from ... add obj files to FCPX enabling 3d Model editing,” said ... between professional and armature, FCPX 3D Model is a definite ... Final Cut Pro X users to upload and control 3D ...
Breaking Medicine News(10 mins):Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:Forbes Living TV Announces Winner of Thanksgiving #PayItForward Contest 2Health News:Pixel Film Studios released FCPX 3D Model plugin Exclusively for Final Cut Pro X 2
... Government plans to hasten patient treatment has included bestowing ... drugs//. ,Under this plan, nurses and pharmacists ... for common illnesses that range from acne to tonsillitis. ... clinics and will soon be able to prescribe drugs ...
... industry a panel comprising European experts recommended Sanofi-Aventis's anti-obesity pill ... news was brought to light by the company itself. ... block a pleasure centre and so fight obesity. People on ... with eating. ,Data from a trial involving more ...
... College of Nursing congress last week shouted at Patricia Hewitt ... their hostility to a government which was a great ally ... and what are they furious about? There are 70,000 nurses ... has also risen considerably over the past three years. Les ...
... in the May issue of the journal Medical Care say ... alright to discuss religion with their patients.// However, only three ... beliefs and only half of them bother to query a ... ten physicians routinely mentions his or her religious beliefs and ...
... the rain, there seems to be enough shine, making Washington, ... to the Environmental// Protection Agency. , ,The ... to schools that comprise of 40 activity cards and a ... the sun's UV rays. , ,Demonstrators apply ...
... occur in children whose mothers report difficulties with substance ... delivery, reports a study published in the Archives of ... / mood disorders, smoking, maternal drinking, substance or drug ... that can contribute to behavior problems in children. Although ...
Cached Medicine News:Health News:Doctors' Response To Patients' Religious Beliefs Can Vary 2Health News:Doctors' Response To Patients' Religious Beliefs Can Vary 3Health News:Maternal Difficulties Increase Risk of Behavior Problems in Children 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: